Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics executive Golden Lee Scott reported an automatic share sale related to tax withholding. On January 8, 2026, Scott sold 866 shares of PTC Therapeutics common stock at $76.45 per share. After this transaction, Scott beneficially owned 92,428 shares of common stock in direct form.
According to the footnote, the sale was made automatically under an irrevocable "sell to cover" election entered into when the equity awards were granted. The sale was used to satisfy tax withholding obligations tied to the vesting of 3,539 restricted stock units (RSUs) from January 7, 2022 grants that originally totaled 14,155 RSUs. This indicates the transaction was administrative in nature and connected to previously granted equity compensation.
PTC Therapeutics executive Mark Elliott Boulding reported multiple open-market sales of company common stock. As Executive Vice President and Chief Legal Officer, he filed a Form 4 showing several sales on January 8 and 9, 2026 at per-share prices in the mid-to-high $70s. Individual transactions included sales such as 2,482 shares at a weighted average price of $76.56 and 1,521 shares at a weighted average price of $77.46, with all shares held directly.
After the reported sales, Boulding beneficially owned slightly more than 111,000 shares of PTC Therapeutics common stock. One block of 1,286 shares was automatically sold under an irrevocable “sell to cover” election to satisfy tax withholding tied to the vesting of 3,600 restricted stock units from a 2022 equity grant. The filing notes that the sales were carried out under a written Rule 10b5‑1 trading plan adopted on December 4, 2024, with several prices disclosed as weighted averages over narrow trading ranges.
PTC Therapeutics, Inc. reported insider share sales by its Chief Technical Ops Officer, Neil Gregory Almstead, related to tax withholding on equity awards. On January 8, 2026, Almstead automatically sold 881 shares of common stock at $76.45 per share under a sell-to-cover election tied to the vesting of 3,600 RSUs from a January 7, 2022 grant of 14,400 RSUs.
On the same date, 59 additional shares of common stock were automatically sold at $76.45 per share, held indirectly through his spouse, to cover taxes on the vesting of 195 RSUs from a January 7, 2022 grant of 780 RSUs. After these transactions, Almstead beneficially owned 115,196 shares directly and 6,791 shares indirectly through his spouse.
PTC Therapeutics released preliminary, unaudited 2025 figures and issued 2026 guidance. For the year ending December 31, 2025, it expects to report total net product and royalty revenue of approximately $823.4 million, including total net product revenue of about $587.8 million and net product revenue for Sephience™ (sepiapterin) of roughly $112.1 million. Final results will follow completion of the year-end audit.
For 2026, the company anticipates full-year total product revenues of $700 million to $800 million, excluding Evrysdi® royalty and collaboration revenue. It projects GAAP R&D and SG&A expenses of $775 million to $815 million and non-GAAP R&D and SG&A expenses of $680 million to $720 million, excluding an estimated $95 million of non-cash stock-based compensation. PTC plans to discuss these figures and 2026 milestones at the J.P. Morgan Healthcare Conference and then enter an investor quiet period.
A shareholder filed a Form 144 notice to sell 2,314 shares of common stock through Fidelity Brokerage Services LLC, with an aggregate market value of $180,314.42. The shares are part of an outstanding base of 80,288,305 shares and are expected to be sold on or about January 9, 2026 on the NASDAQ exchange.
The seller acquired these 2,314 shares on January 7, 2026 via restricted stock vesting from the issuer as compensation. The filing also lists prior open-market sales over the past three months by Mark Boulding, including 4,879 shares sold on January 7, 2026 for $377,839.55, alongside several other transactions with six‑figure gross proceeds.
Form 144 discloses a planned sale of 2,746 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of 213,888.74. These shares relate to an issuer with 80,288,305 common shares outstanding and are expected to be sold on or about 01/09/2026 on the NASDAQ exchange.
The securities to be sold were acquired on 01/07/2026 via restricted stock vesting from the issuer as compensation, in the same amount of 2,746 shares. The notice also lists earlier sales over the prior three months by Eric Pauwels, including 40,290 common shares sold on 12/17/2025 for gross proceeds of 3,038,755.33, along with smaller transactions on several subsequent dates in December 2025 and January 2026.
PTC Therapeutics senior executive Christine Marie Utter reported automatic stock sales linked to restricted stock unit (RSU) vesting. As SVP and Chief Accounting Officer, she sold 1,381 shares of common stock at $76.95 on January 6, 2026 and 1,235 shares at $77.45 on January 7, 2026.
According to the footnotes, both sales were made under irrevocable “sell to cover” elections entered into when the RSU grants were accepted, solely to satisfy tax withholding obligations on the vesting of 3,500 RSUs from separate 14,000‑share grants. After these transactions, she directly owns 73,727 shares of PTC Therapeutics common stock.
PTC Therapeutics’ chief financial officer, Pierre Gravier, reported an automatic sale of company stock tied to RSU vesting. On 01/06/2026, he sold 2,139 shares of PTC Therapeutics common stock at a price of $76.95 per share. The filing states these shares were sold pursuant to an irrevocable “sell to cover” election entered into when he accepted the grant, in order to satisfy tax withholding obligations on the vesting of 5,625 restricted stock units (RSUs) from a January 3, 2025 grant of 22,500 RSUs. Following this tax-related sale, he beneficially owned 90,310 shares of PTC Therapeutics common stock directly.
PTC Therapeutics, Inc. (PTCT) chief business officer Eric Pauwels reported automatic sales of common stock to cover tax withholding from restricted stock unit (RSU) vesting. On January 6, 2026, he sold 1,789 shares of common stock at $76.95 per share. On January 7, 2026, he sold an additional 1,352 shares at $77.48 per share. Both transactions were executed under an irrevocable sell-to-cover election entered into when the RSU grants were accepted and were made to satisfy tax withholding obligations tied to the vesting of RSUs granted in January 2023 and January 2025. After these transactions, Pauwels directly beneficially owned 87,489 shares of PTC Therapeutics common stock.
PTC Therapeutics, Inc. (PTCT) CEO Matthew B. Klein reported automatic sales of common stock tied to RSU vesting. On January 6, 2026, 5,149 shares of common stock were sold at $76.95 per share, and on January 7, 2026, 3,016 shares were sold at $77.48 per share. Both transactions are coded as sales and are reported as directly owned shares.
According to the footnotes, these sales were made under irrevocable "sell to cover" elections to satisfy tax withholding obligations arising from the vesting of 17,500 RSUs from a January 3, 2025 grant of 70,000 RSUs and 6,500 RSUs from a January 5, 2023 grant of 26,000 RSUs. After these transactions, Klein directly beneficially owns 396,967 shares of PTC Therapeutics common stock.